BioNTech SE

NasdaqGS:BNTX Lagerbericht

Marktkapitalisierung: US$27.1b

BioNTech Management

Management Kriterienprüfungen 4/4

BioNTech CEO ist Ugur Sahin , ernannt in Jan 2008, hat eine Amtszeit von 16.83 Jahren. Die jährliche Gesamtvergütung beträgt €3.06M , bestehend aus 22.9% Gehalt und 77.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 17.23% der Aktien des Unternehmens, im Wert von $4.67B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 4.6 Jahre.

Wichtige Informationen

Ugur Sahin

Geschäftsführender

€3.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts22.9%
Amtszeit als Geschäftsführer16.8yrs
Eigentum des Geschäftsführers17.2%
Durchschnittliche Amtszeit des Managements3.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.6yrs

Jüngste Management Updates

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11
Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Recent updates

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

Nov 06

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Nov 06
BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

BioNTech's Oncology Gamble: High Stakes, Big Potential

Oct 21

BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

Sep 13
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Aug 20

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

Jun 16
Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11
Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08
Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24
BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09
BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18
Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02
Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22
Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11
BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13
Is BioNTech (NASDAQ:BNTX) A Risky Investment?

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23
A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29
BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ugur Sahin im Vergleich zu den Einnahmen von BioNTech verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-€467m

Jun 30 2024n/an/a

-€504m

Mar 31 2024n/an/a

€113m

Dec 31 2023€3m€700k

€930m

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€4b

Mar 31 2023n/an/a

€6b

Dec 31 2022€6m€360k

€9b

Sep 30 2022n/an/a

€10b

Jun 30 2022n/an/a

€12b

Mar 31 2022n/an/a

€13b

Dec 31 2021€12m€360k

€10b

Sep 30 2021n/an/a

€7b

Jun 30 2021n/an/a

€4b

Mar 31 2021n/an/a

€1b

Dec 31 2020€17m€360k

€15m

Sep 30 2020n/an/a

-€410m

Jun 30 2020n/an/a

-€230m

Mar 31 2020n/an/a

-€192m

Dec 31 2019€7m€311k

-€179m

Sep 30 2019n/an/a

-€122m

Jun 30 2019n/an/a

-€116m

Mar 31 2019n/an/a

-€77m

Dec 31 2018€653k€210k

-€48m

Vergütung im Vergleich zum Markt: UgurDie Gesamtvergütung ($USD3.18M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.66M).

Entschädigung vs. Einkommen: UgurDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Ugur Sahin (59 yo)

16.8yrs

Amtszeit

€3,056,000

Vergütung

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Ugur Sahin
Co-Founder16.8yrs€3.06m17.23%
$ 4.7b
Ozlem Tureci
Co-Founder6.8yrs€814.00k0.38%
$ 103.3m
Jens Holstein
CFO & Member of Management Board3.3yrs€1.32m0.00068%
$ 184.4k
Sierk Poetting
MD, COO & Member of Management Board10.8yrs€821.00k0.31%
$ 85.4m
Ryan Richardson
Chief Strategy Officer4.8yrs€1.41m0.0061%
$ 1.7m
James Timothy Ryan
Chief Legal & Business Officer & Member of the Management Board1.2yrs€848.00kkeine Daten
Sean Marett
Executive Officerless than a year€133.00k0.34%
$ 92.2m
Lisa Birringer
Senior Vice President of Global Financial Reporting & Accountingless than a yearkeine Datenkeine Daten
Zach Taylor
Senior Vice President of Corporate Development & Strategyless than a yearkeine Datenkeine Daten
Katalin Kariko
Senior VP & External Consultant for RNA Protein Replacement Therapiesno datakeine Datenkeine Daten
Oliver Henning
Senior Vice President of Operationsno datakeine Datenkeine Daten
Sebastian Kreiter
Senior Vice President of Immunotherapy & Preclinical Researchno datakeine Datenkeine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: BNTXDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Rudolf Staudigl
Supervisory Board Member2.4yrs€90.00k0.00017%
$ 46.1k
Ulrich Wandschneider
Independent Deputy Chairman Supervisory Board6.8yrs€114.00kkeine Daten
Michael Motschmann
Independent Supervisory Board Member16.8yrs€80.00kkeine Daten
Helmut Jeggle
Independent Supervisory Board Chairman16.8yrs€226.00k0.14%
$ 37.6m
Nicola Blackwood
Member of Supervisory Board1.5yrs€46.00kkeine Daten
Anja Morawietz
Supervisory Board Member2.4yrs€105.00k0.00010%
$ 27.1k

4.6yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: BNTXDie Vorstandsmitglieder gelten als erfahren (4.6 Jahre durchschnittliche Amtszeit).